Gene editing trial for X-linked chronic granulomatous disease
Treatments studied
Part of Blood & lymphatic, Genetic & congenital, Immune system & allergy clinical trials.
This trial tests a new gene-editing treatment for men with a specific genetic mutation that causes X-linked chronic granulomatous disease (CGD). The goal is to fix the faulty gene in your own blood stem cells to help your immune system fight infections better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be a male age 18 or older.
- You must have the CYBB c.676 C>T gene mutation confirmed by a blood test.
- You must have had at least one serious infection or inflammation that needed hospital care.
- Your doctor must have told you that your condition has a poor outlook.
- A store of your own blood stem cells must be ready for treatment.
- If you are sexually active, you and your partner must use effective birth control during and for 6 months after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new gene therapy for X-linked chronic granulomatous disease (CGD), a condition where the immune system cannot fight certain infections. The treatment uses your own blood stem cells, which are modified in the lab to help your body produce working immune cells.
This study is checking levels of antibodies and immune-signaling molecules (cytokines) in people with chronic granulomatous disease (CGD). It aims to better understand the immune system in CGD, which may help with future treatments.
This trial tests an intensive stem cell transplant approach for people with chronic granulomatous disease (CGD). The study aims to improve outcomes by preparing the body for a donor stem cell graft and using immune “brakes” to reduce immune problems.
This trial tests a gene therapy that uses base-edited stem cells to treat X-SCID, a genetic immune disorder. It may help improve immune function and reduce infections in patients who still have low immune cells or severe infections despite previous treatments.
This early-phase trial tests whether an mRNA-based treatment can correct a key immune problem in people with chronic granulomatous disease (CGD). It may help your immune cells work better against infections, but this is mainly to check safety and early signs of benefit.
This trial tests a new gene therapy for people with a specific type of chronic granulomatous disease (p47 CGD). The treatment uses your own blood stem cells, which are modified in a lab to help your body fight infections better. It is for people who do not have a matched stem cell donor and have had serious infections.
Hear when a new Chronic Granulomatous Disease (CGD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.